Answers are grounded in this paper and cite their sources.
Despite several decades of dedicated R&D, fusion, a potentially world-changing energy source, remains decades away from commercialisation. The majority of development thus far has been via publicly-funded programmes led by government laboratories focused on scientific research and in which commercialisation strategy and innovation play a minor role. Generally, such programmes follow a linear model of innovation in which commercial aspects are not considered until later in development. In consequence and without intention, devices not well-suited for commercial application are being pursued. In recent years, however, privately funded fusion start-ups have emerged with the goal of accelerating the commercialisation of fusion. Fusion start-ups are, by necessity, operating on a fundamentally different model of innovation: agile innovation, whereby technology is developed flexibly and iteratively towards an explicit commercial goal. Technology Roadmapping is a method that has been effective for supporting agile innovation but thus far has had limited application to mission-led hardware development. We characterise the key features of the fusion innovation approach and create a novel Technology Roadmapping process for fusion start-ups, which is developed via a case study with Tokamak Energy Ltd. The main elements of the developed process, the resulting Technology Roadmap, and its impact are presented.
No takes yet. Share an insight, caveat, or question.
Pearson et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: